| Medical and Health Sciences | Lifetime | 5 | GB 2 | 100.00 |
| Medical and Health Sciences | 2021-2025 | 2 | GB 1 | 100.00 |
| Economics and Finance | 2021-2025 | 332 | GB 19 | 98.93 |
| Cardiology and Cardiovascular Medicine | Lifetime | 3 | GB 1 | 100.00 |
| Internal Medicine | Lifetime | 1 | GB 1 | 99.95 |
| Epidemiology | Lifetime | 55 | GB 3 | 99.91 |
| Surgery | Lifetime | 439 | GB 28 | 99.62 |
| Econometrics and Quantitative Economics | Lifetime | 708 | GB 64 | 99.34 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 351 | GB 32 | 99.17 |
| Pulmonary and Respiratory Medicine | Lifetime | 505 | GB 36 | 99.30 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 378 | GB 47 | 98.87 |
| Complementary and Alternative Medicine | Lifetime | 325 | GB 30 | 98.38 |
| Clinical Neurology | Lifetime | 756 | GB 76 | 95.88 |
| Nutrition and Dietetics | Lifetime | 950 | GB 84 | 95.20 |
| Hematology | Lifetime | 658 | GB 55 | 94.61 |
| Cancer Research | Lifetime | 965 | GB 60 | 92.60 |
| Obstetrics and Gynecology | Lifetime | 633 | GB 88 | 93.09 |
| Emergency Medicine | Lifetime | 909 | GB 79 | 88.56 |
| Nephrology | Lifetime | 850 | GB 54 | 86.12 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 2 | GB 1 | 99.99 |
| Epidemiology | 2021-2025 | 13 | GB 2 | 99.94 |
| Internal Medicine | 2021-2025 | 2 | GB 1 | 99.70 |
| Surgery | 2021-2025 | 124 | GB 8 | 99.30 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 56 | GB 8 | 99.28 |
| Econometrics and Quantitative Economics | 2021-2025 | 241 | GB 12 | 98.96 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 115 | GB 10 | 98.03 |
| Clinical Neurology | 2021-2025 | 94 | GB 17 | 97.92 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 314 | GB 24 | 97.06 |
| Public, Environmental and Occupational Health | 2021-2025 | 542 | GB 51 | 94.79 |
| Medical Physiology | 2021-2025 | 421 | GB 45 | 94.07 |
| Infectious Diseases | 2021-2025 | 416 | GB 41 | 91.71 |
| Health, Toxicology and Mutagenesis | 2021-2025 | 498 | GB 28 | 90.86 |
| Pediatrics, Perinatology and Child Health | 2021-2025 | 473 | GB 58 | 88.26 |
| Psychiatry and Mental health | 2021-2025 | 448 | GB 58 | 87.95 |
| Pathology and Forensic Medicine | 2021-2025 | 405 | GB 26 | 83.73 |
| Medical Genetics | 2021-2025 | 320 | GB 13 | 79.37 |
| Nephrology | 2021-2025 | 285 | GB 14 | 78.10 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 1 | GB 1 | 100.00 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 1 | GB 1 | 100.00 |
| Cardiac Arrhythmias and Treatments | Lifetime | 1 | GB 1 | 100.00 |
| Acute Ischemic Stroke Management | Lifetime | 2 | GB 1 | 99.97 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 2 | GB 1 | 99.99 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 8 | GB 2 | 99.96 |
| Blood Pressure and Hypertension Studies | Lifetime | 11 | GB 2 | 99.92 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 13 | GB 3 | 99.92 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 3 | GB 1 | 99.86 |
| Angiogenesis and VEGF in Cancer | Lifetime | 22 | GB 2 | 99.76 |
| Cardiac Imaging and Diagnostics | Lifetime | 56 | GB 5 | 99.88 |
| Cardiac Health and Mental Health | Lifetime | 22 | GB 6 | 99.66 |
| Cardiovascular Health and Disease Prevention | Lifetime | 32 | GB 7 | 99.70 |
| Cardiovascular Function and Risk Factors | Lifetime | 78 | GB 6 | 99.83 |
| Cardiovascular Disease and Adiposity | Lifetime | 49 | GB 2 | 99.64 |
| Heart Rate Variability and Autonomic Control | Lifetime | 83 | GB 6 | 99.53 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 41 | GB 1 | 99.53 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 65 | GB 7 | 99.58 |
| Blood properties and coagulation | Lifetime | 34 | GB 4 | 99.30 |
| Heart Failure Treatment and Management | Lifetime | 74 | GB 4 | 99.71 |
| Peripheral Artery Disease Management | Lifetime | 60 | GB 5 | 99.33 |
| Cerebrovascular and Carotid Artery Diseases | Lifetime | 120 | GB 11 | 99.55 |
| Acute Myocardial Infarction Research | Lifetime | 89 | GB 4 | 99.71 |
| COVID-19 Clinical Research Studies | Lifetime | 185 | GB 18 | 99.06 |
| Cardiac Fibrosis and Remodeling | Lifetime | 26 | GB 1 | 99.36 |
| Long-Term Effects of COVID-19 | Lifetime | 96 | GB 19 | 98.87 |
| Cardiac pacing and defibrillation studies | Lifetime | 110 | GB 3 | 99.56 |
| COVID-19 and healthcare impacts | Lifetime | 105 | GB 24 | 97.87 |
| Blood Coagulation and Thrombosis Mechanisms | Lifetime | 93 | GB 10 | 99.04 |
| Lipoproteins and Cardiovascular Health | Lifetime | 147 | GB 14 | 99.26 |
| Hormonal Regulation and Hypertension | Lifetime | 212 | GB 25 | 98.84 |
| Vitamin K Research Studies | Lifetime | 37 | GB 3 | 98.09 |
| Cardiovascular Syncope and Autonomic Disorders | Lifetime | 115 | GB 9 | 98.56 |
| Cardiac tumors and thrombi | Lifetime | 172 | GB 12 | 98.23 |
| Intracerebral and Subarachnoid Hemorrhage Research | Lifetime | 183 | GB 18 | 98.52 |
| Extracellular vesicles in disease | Lifetime | 344 | GB 7 | 97.09 |
| Cardiovascular and exercise physiology | Lifetime | 424 | GB 36 | 98.17 |
| Pregnancy and preeclampsia studies | Lifetime | 598 | GB 98 | 97.99 |
| Lymphatic System and Diseases | Lifetime | 113 | GB 7 | 96.91 |
| Coronary Interventions and Diagnostics | Lifetime | 586 | GB 31 | 98.35 |
| Protease and Inhibitor Mechanisms | Lifetime | 434 | GB 33 | 97.32 |
| Diabetes Treatment and Management | Lifetime | 622 | GB 69 | 97.78 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 590 | GB 60 | 98.13 |
| Healthcare Systems and Public Health | Lifetime | 253 | GB 2 | 95.70 |
| Lipid metabolism and disorders | Lifetime | 266 | GB 20 | 97.05 |
| Immune cells in cancer | Lifetime | 852 | GB 57 | 95.97 |
| Platelet Disorders and Treatments | Lifetime | 628 | GB 46 | 96.92 |
| Cardiovascular Issues in Pregnancy | Lifetime | 452 | GB 49 | 96.62 |
| Cardiovascular Effects of Exercise | Lifetime | 757 | GB 64 | 96.14 |
| Pharmacology and Obesity Treatment | Lifetime | 366 | GB 26 | 96.03 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 293 | GB 12 | 94.39 |
| Clinical practice guidelines implementation | Lifetime | 599 | GB 114 | 94.37 |
| ECG Monitoring and Analysis | Lifetime | 570 | GB 31 | 94.98 |
| Cardiovascular and Diving-Related Complications | Lifetime | 450 | GB 24 | 94.76 |
| Medication Adherence and Compliance | Lifetime | 470 | GB 33 | 94.09 |
| Cardiovascular Health and Risk Factors | Lifetime | 520 | GB 35 | 93.88 |
| Health Promotion and Cardiovascular Prevention | Lifetime | 344 | GB 69 | 93.81 |
| Renin-Angiotensin System Studies | Lifetime | 755 | GB 49 | 93.94 |
| Signaling Pathways in Disease | Lifetime | 961 | GB 63 | 92.19 |
| Biomarkers in Disease Mechanisms | Lifetime | 332 | GB 19 | 90.07 |
| Apelin-related biomedical research | Lifetime | 417 | GB 38 | 90.69 |
| Sodium Intake and Health | Lifetime | 521 | GB 30 | 92.84 |
| Potassium and Related Disorders | Lifetime | 748 | GB 46 | 87.76 |
| Heart rate and cardiovascular health | Lifetime | 225 | GB 23 | 86.79 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 788 | GB 51 | 87.67 |
| Pharmaceutical industry and healthcare | Lifetime | 618 | GB 59 | 84.95 |
| Takotsubo Cardiomyopathy and Associated Phenomena | Lifetime | 474 | GB 23 | 83.72 |
| GDF15 and Related Biomarkers | Lifetime | 535 | GB 30 | 81.27 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 1 | GB 1 | 100.00 |
| Acute Ischemic Stroke Management | 2021-2025 | 1 | GB 1 | 99.93 |
| Cardiac Arrhythmias and Treatments | 2021-2025 | 1 | GB 1 | 99.99 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 1 | GB 1 | 99.98 |
| Cardiac electrophysiology and arrhythmias | 2021-2025 | 1 | GB 1 | 99.97 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 3 | GB 2 | 99.87 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 1 | GB 1 | 99.98 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 3 | GB 1 | 99.84 |
| Cardiac Health and Mental Health | 2021-2025 | 3 | GB 1 | 99.70 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 16 | GB 5 | 99.81 |
| Long-Term Effects of COVID-19 | 2021-2025 | 30 | GB 10 | 99.34 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 42 | GB 5 | 99.71 |
| COVID-19 Clinical Research Studies | 2021-2025 | 156 | GB 16 | 99.12 |
| Heart Rate Variability and Autonomic Control | 2021-2025 | 35 | GB 2 | 98.65 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 53 | GB 6 | 99.20 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 34 | GB 5 | 97.66 |
| Chronic Disease Management Strategies | 2021-2025 | 43 | GB 19 | 97.99 |
| Cerebrovascular and Carotid Artery Diseases | 2021-2025 | 83 | GB 4 | 98.70 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 47 | GB 3 | 98.92 |
| COVID-19 and healthcare impacts | 2021-2025 | 131 | GB 29 | 97.02 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 31 | GB 1 | 97.69 |
| Diabetes Treatment and Management | 2021-2025 | 108 | GB 14 | 98.73 |
| Cardiac tumors and thrombi | 2021-2025 | 25 | GB 3 | 97.29 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 375 | GB 15 | 98.15 |
| Cardiovascular Syncope and Autonomic Disorders | 2021-2025 | 26 | GB 3 | 96.99 |
| Heart Failure Treatment and Management | 2021-2025 | 124 | GB 14 | 98.55 |
| Acute Myocardial Infarction Research | 2021-2025 | 127 | GB 22 | 97.89 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 102 | GB 6 | 96.93 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 88 | GB 10 | 96.92 |
| Clinical practice guidelines implementation | 2021-2025 | 53 | GB 5 | 94.74 |
| Intracerebral and Subarachnoid Hemorrhage Research | 2021-2025 | 104 | GB 8 | 95.80 |
| ECG Monitoring and Analysis | 2021-2025 | 111 | GB 8 | 94.29 |
| Alcohol Consumption and Health Effects | 2021-2025 | 104 | GB 5 | 94.82 |
| Frailty in Older Adults | 2021-2025 | 316 | GB 29 | 94.42 |
| Diet and metabolism studies | 2021-2025 | 808 | GB 59 | 93.13 |
| Vitamin K Research Studies | 2021-2025 | 19 | GB 1 | 89.92 |
| Cardiac, Anesthesia and Surgical Outcomes | 2021-2025 | 957 | GB 100 | 92.94 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 271 | GB 14 | 91.69 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 119 | GB 8 | 91.91 |
| Diet, Metabolism, and Disease | 2021-2025 | 350 | GB 10 | 91.28 |
| Diabetes Management and Research | 2021-2025 | 709 | GB 68 | 92.41 |
| Cardiovascular Effects of Exercise | 2021-2025 | 468 | GB 54 | 89.12 |
| Peripheral Artery Disease Management | 2021-2025 | 628 | GB 38 | 87.43 |
| Epilepsy research and treatment | 2021-2025 | 776 | GB 47 | 88.87 |
| Healthcare Systems and Public Health | 2021-2025 | 362 | GB 2 | 84.66 |
| Cardiovascular and exercise physiology | 2021-2025 | 859 | GB 66 | 86.79 |
| Neuroprotection in Stroke and Neurodegeneration | 2021-2025 | 287 | GB 7 | 81.51 |
| Medication Adherence and Compliance | 2021-2025 | 358 | GB 22 | 82.93 |
| Potassium and Related Disorders | 2021-2025 | 267 | GB 15 | 78.37 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 880 | GB 28 | 76.73 |
| Blood Coagulation and Thrombosis Mechanisms | 2021-2025 | 455 | GB 25 | 78.45 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 206 | GB 26 | 73.86 |
| Machine Learning in Healthcare | 2021-2025 | 806 | GB 65 | 77.02 |
| Takotsubo Cardiomyopathy and Associated Phenomena | 2021-2025 | 167 | GB 15 | 74.85 |
| Gastroesophageal reflux and treatments | 2021-2025 | 961 | GB 44 | 77.16 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 765 | GB 41 | 74.92 |
| GDF15 and Related Biomarkers | 2021-2025 | 288 | GB 20 | 69.04 |
| Healthcare Systems and Practices | 2021-2025 | 709 | GB 11 | 68.19 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 670 | GB 61 | 62.03 |
| Blood properties and coagulation | 2021-2025 | 936 | GB 62 | 53.71 |
| Neurological and metabolic disorders | 2021-2025 | 647 | GB 20 | 44.85 |
| Pharmaceutical industry and healthcare | 2021-2025 | 430 | GB 31 | 46.12 |
| Cerebrovascular and genetic disorders | 2021-2025 | 988 | GB 64 | 20.05 |
| Apelin-related biomedical research | 2021-2025 | 943 | GB 26 | 18.63 |
| Case Reports on Hematomas | 2021-2025 | 580 | GB 21 | 19.41 |